CLAIMS

1. Use of a pharmaceutically acceptable amount of niraparib or a salt thereof in the manufacture of a medicament for the treatment of metastatic castration-sensitive prostate cancer in a human in need thereof, wherein the human is carrying at least one DNA repair anomaly in a gene selected from the group consisting of *BRCA-1*, *BRCA-2*, *FANCA*, *PALB2*, *CHEK2*, and *BRIP1*.

2. The use of claim 1, wherein the niraparib or a salt thereof is to be administered in combination with androgen deprivation therapy.

3. The use of claim 2, wherein the androgen deprivation therapy comprises a luteinizing hormone-releasing hormone antagonist or agonist, or orchiectomy.

4. The use of claim 1, wherein niraparib or a salt thereof is to be administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.

5. The use of claim 1, wherein niraparib or a salt thereof is to be administered in an amount of about 200 mg niraparib/day.

6. The use of claim 1, wherein niraparib or a salt thereof is to be administered in an amount of about 300 mg niraparib/day.

7. The use of claim 6, wherein niraparib or a salt thereof is to be administered orally, once daily, in 100 mg niraparib oral dosage forms.

8. The use of claim 1, wherein the human has had at least one line of taxane-based chemotherapy.

9. The use of claim 1, wherein the DNA repair anomaly is a genomic lesion.

10. The use of claim 9, wherein the genomic lesion is a homozygous deletion, heterozygous deletion plus deleterious mutation, or copy neutral loss of heterozygosity plus deleterious mutation.

11. Use of a therapeutically effective amount of niraparib or a salt thereof in the manufacture of a medicament for the treatment of metastatic castration-sensitive prostate cancer in a human in need thereof, wherein the human is carrying at least one DNA repair anomaly in a gene selected from the group consisting of *BRCA-1, BRCA-2, FANCA, PALB2, CHEK2,* and *BRIP1.*

12. The use of claim 11, wherein the niraparib or a salt thereof is to be administered in combination with androgen deprivation therapy.

13. The use of claim 12, wherein the androgen deprivation therapy comprises a luteinizing hormone-releasing hormone antagonist or agonist, or orchiectomy.

14. The use of claim 11, wherein niraparib or a salt thereof is to be administered in an amount of from about 30 mg niraparib/day to about 400 mg niraparib/day.

15. The use of claim 11, wherein niraparib or a salt thereof is to be administered in an amount of about 200 mg niraparib/day.

16. The use of claim 11, wherein niraparib or a salt thereof is to be administered in an amount of about 300 mg niraparib/day.

17. The use of claim 11, wherein niraparib or a salt thereof is to be administered orally, once daily, in 100 mg niraparib oral dosage forms.

18. The use of claim 11, wherein the human has had at least one line of taxane-based chemotherapy.

19. The use of claim 11, wherein the DNA repair anomaly is a genomic lesion.

20. The use of claim 19, wherein the genomic lesion is a homozygous deletion, heterozygous deletion plus deleterious mutation, or copy neutral loss of heterozygosity plus deleterious mutation.